Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-07-24

FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for Norvasc (amlodipine besylate) resulting in updates to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NORVASC (amlodipine besylate)

Snippet

SUPPL AP for NORVASC (AMLODIPINE BESYLATE)